Medpace (NASDAQ:MEDP) Sets New 1-Year High – Here’s What Happened

Medpace Holdings, Inc. (NASDAQ:MEDP) shares reached a new 52-week high on Friday . The stock traded as high as $628.92 and last traded at $620.76, with a volume of 41588 shares trading hands. The stock had previously closed at $618.04.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. TD Cowen upped their target price on shares of Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a research note on Friday, October 24th. Robert W. Baird set a $613.00 price objective on shares of Medpace in a research report on Friday, October 24th. Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, December 20th. Truist Financial set a $555.00 price target on Medpace in a report on Monday, October 27th. Finally, BMO Capital Markets began coverage on Medpace in a research report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price objective for the company. Two analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat.com, Medpace currently has a consensus rating of “Reduce” and a consensus price target of $491.27.

Medpace Price Performance

The firm has a market cap of $17.50 billion, a P/E ratio of 43.47, a PEG ratio of 2.07 and a beta of 1.43. The stock’s 50 day moving average is $582.30 and its two-hundred day moving average is $507.97.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm had revenue of $659.90 million during the quarter, compared to analysts’ expectations of $640.49 million. During the same quarter last year, the company earned $3.01 earnings per share. The company’s revenue for the quarter was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Activity at Medpace

In other news, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the sale, the vice president owned 27,500 shares in the company, valued at approximately $16,751,625. The trade was a 42.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kevin M. Brady sold 3,000 shares of the company’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the completion of the sale, the chief financial officer directly owned 6,000 shares in the company, valued at approximately $3,542,100. The trade was a 33.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 387,925 shares of company stock valued at $233,386,647 in the last 90 days. 20.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Medpace

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Fifth Third Wealth Advisors LLC increased its holdings in shares of Medpace by 2.6% during the third quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock worth $379,000 after buying an additional 19 shares in the last quarter. BOKF NA grew its position in Medpace by 0.8% during the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after acquiring an additional 20 shares during the last quarter. HighPoint Advisor Group LLC increased its holdings in Medpace by 2.8% during the 3rd quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock valued at $416,000 after purchasing an additional 22 shares in the last quarter. Kaufman Rossin Wealth LLC raised its position in Medpace by 3.4% in the 4th quarter. Kaufman Rossin Wealth LLC now owns 795 shares of the company’s stock valued at $447,000 after purchasing an additional 26 shares during the last quarter. Finally, Portside Wealth Group LLC raised its position in Medpace by 2.5% in the 2nd quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock valued at $342,000 after purchasing an additional 27 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.